Melville, NY --News Direct-- BioRestorative Therapies, Inc.

Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.

One flourishing field in biotech is regenerative medicine, a market worth $16.9 billion in 2021. Regenerative medicine harnesses the body’s amazing ability to heal itself, using cutting-edge technology to apply this regenerative power to prompt the body to recover from diseases previously uncured.a

An estimated one-third of Americans would benefit from regenerative therapeutic cures. There are wide applications for such regenerative therapy, with categories including stem cell research, gene therapy and tissue engineering. Some difficulties for regenerative medicine companies include arduous Food and Drug Administration (FDA) trial processes and the need for vertical integration of their product development to cut expenses.

Biotech companies involved in regenerative medicine include Mesoblast Ltd. (NASDAQ: MESO), Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), Lineage Cell Therapeutics (NYSE: LCTX) and BioRestorative Therapies Inc. (NASDAQ: BRTX).

Here is a look at some companies looking to be leaders in the regenerative therapy field:

Mesoblast Ltd. develops novel treatments for back pain and various cardiovascular conditions. This Australia-based company focuses primarily on cell therapy solutions, with a mesenchymal lineage stem cell (MSC) technology platform. This develops MSCs, highly multipotent cells taken from healthy bone marrow, and develops treatments for tissue damage, heart disease and more.

Lineage Cell Therapeutics is a company pioneering cell-based therapies to treat serious diseases, including ocular disorders and cancer. It uses its proprietary cell-therapy platform to develop and manufacture self-renewing stem cells into differentiated cells, which can be transplanted to treat problems including cancer or degenerative diseases.

Brainstorm Therapeutics focuses on cell therapies for neurodegenerative diseases. Its autologous cellular therapeutics platform NurOwn® treats the disease by differentiating the patient’s healthy MSCs. Brainstorm’s work may eventually provide treatments for such neurodegenerative diseases as Alzheimer’s.

BioRestorative Therapies, which primarily develops products using highly therapeutic adult stem cells, focuses on disc/spine disease and metabolic disorders. BioRestorative’s brtxDisc program is developing a treatment for the millions of Americans suffering from either chronic or acute back pain. Its product BRTX-100, which uses autologous stem cells to treat degenerative spinal discs, is in a Phase Two FDA trial.

BioRestorative is also tackling obesity, which currently affects over 40% of Americans. It is developing the product ThermoStemⓇ, which harnesses the body’s natural production of healthy brown fat cells to target patient obesity and other metabolic issues associated with obesity.

BioRestorative believes that its treatments will also help condition the body for better future regeneration and responses to medical treatment. A significant advantage for the company is the vertical integration of development and production it has through its clinical-grade cell therapy manufacturing facility. This facility, completed in April, gives BioRestorative control and oversight in the cell manufacturing process, apart from the flexibility to make its own decisions and to correct quality issues in real-time. Owning the facility mitigates the expense normally associated with these activities, which is a great benefit when conducting FDA trials.

Learn more about BioRestorative by visiting its website.

BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

View source version on newsdirect.com: https://newsdirect.com/news/a-look-at-some-of-the-companies-innovating-in-the-cutting-edge-regenerative-medicine-field-188108312

Relmada stock crashed Thursday after its depression treatment failed a final-phase test, helping bolster rival Axsome. AXSM stock surged.

Demand for the medication has surged since the government made it easier to get through telehealth appointments.

Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.

The change represents Gilead's focus on research, now concentrated on the south section of its 72-acre Foster City campus.

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

In this article, we discuss 10 best gene editing stocks to buy. If you want to see more stocks in this selection, check out 5 Best Gene Editing Stocks To Buy. A report by The Wall Street Journal dated September 16 suggests that Intellia Therapeutics, Inc. (NASDAQ:NTLA) revealed positive early-stage trial results for its CRISPR […]

VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.

SIGA Technologies Inc (NASDAQ: SIGA) provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, the company initiated trials in the U.S., the U.K., and Congo to further assess the safety and efficacy of TPOXX in participants with monkeypox. These randomized clinical trials are now enrolling patients. Study of Tecovirimat for Human Monkeypox Virus (STOMP; A5418) is a U.S.-based clinical trial sponsored

Follow these five steps to make the right decision when open enrollment for Medicare starts on Saturday.

A flurry of announcements Thursday on COVID vaccines and boosters offered further evidence and support for the new bivalent boosters that target the most dominant virus strains and experts are hoping they will persuade more Americans to get the updated shot.

This health stock is up over 9% for the week and within 3% of a buy point on the chart. Shares soared on news of its obesity treatment.

The first quarter of 2021 was a turning point for Shockwave Medical, says Chief Executive Doug Godshall. Since then, SWAV stock has soared.

U.K. drug maker GSK reported partial results from a respiratory syncytial virus vaccine trial that appear to be at least competitive with Pfizer's latest data.

Shares of Novavax Inc. (NVAX) were down 3.4% in premarket trading on Thursday after the company said its combination COVID-19 vaccine and flu shot candidate generated an immune response in a Phase 1/2 clinical trial. Novavax also said that the safety and tolerability of the combination vaccine was consistent with getting a standalone COVID-19 vaccine or flu shot, and it plans to begin a confirmatory Phase 2 clinical trial this year. Novavax’s stock has tumbled 85.8% this year, while the S&P 500 (SPX) has declined 24.7%.

At an event in Boston on Wednesday, CEO Karen Lynch talked of the strategy around recent and planned acquisitions.

Investors often favor that industry during tough times because its earnings are less at risk -- patients can't do without the products these companies sell. Shares of Axsome Therapeutics (NASDAQ: AXSM), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX) have actually been climbing this year, and it doesn't look as if those trends will end any time soon. Axsome Therapeutics attracted investors' attention as it moved closer to product commercialization.

Most patients with COVID-19 who have lingering symptoms at 12 months are likely to still have symptoms at 18 months, new data suggest. Among a subset of 197 survivors of symptomatic SARS-CoV-2 infections who completed surveys at 12 months and 18 months, most reported lingering symptoms at both time points, researchers reported in Nature Communications. Rates of no recovery at 12 months were 11% with 51% partial recovery and 39% complete recovery.

The preliminary data results are the first from human testing of the shots in people at least 18 years old.

As recovery from Hurricane Ian continues, experts warn that some of the worst effects on mental health occur in the year after a natural disaster, especially with all the barriers that can prevent people from seeking help.

MARKET PULSE Shares of Relmada Therapeutics Inc. (RLMD) fell 80.0% in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not meet the primary endpoint in a Phase 3 clinical trial.